Argatroban plus dual antiplatelet therapy: Preliminary evidence for managing early neurological deterioration after lacunar stroke
Research article published in Clinical neurology and neurosurgery (2025)
Abstract
BACKGROUND: This study aimed to evaluate the efficacy and safety of argatroban combined with dual antiplatelet therapy (DAPT) in managing early neurological deterioration (END) following stroke and to determine whether argatroban offers superior outcomes compared to DAPT alone. METHODS: Patients presenting with END after stroke between October 2022 and April 2024 were included and classified into two groups based on their treatment regimen during hospitalization: the argatroban group (argatroban + DAPT) and the control group (DAPT only). Stroke severity was assessed using the National Institutes of Health Stroke Scale (NIHSS) at admission and on days 7, 14, and 90 ± 7 post-stroke. Functional outcomes were evaluated using the modified Rankin Scale (mRS), with scores of 0-2 indicating favorable prognosis based on follow-up records. The argatroban group comprised 30 patients, while the control group included 50 patients. RESULTS: At 7 and 14 days post-treatment, The argatroban group demonstrated a statistically significant reduction in the NIHSS score compared to the control group (2.84 ± 1.32 vs. 3.56 ± 1.49, p = 0.024). Moreover, the reduction in NIHSS scores over the treatment period was significantly greater in the argatroban group than in the control group (p = 0.017). There were significant differences in the distribution of mRS scores at 90 ± 7 days between the two groups (χ2 = 6.162, p = 0.041), although the proportion of favorable outcome with mRS = 0-2 did not reach statistically significance (70 % vs. 62 %; p = 0.47). Gingival bleeding occurred in one patient (3.33 %) in the argatroban group, whereas no cases of bleeding or complications such as gastrointestinal hemorrhage, cerebral hemorrhage, or hepatic/renal dysfunction were observed in either group during the treatment and follow-up period. CONCLUSIONS: Early administration of argatroban combined with DAPT was both safe and effective in improving clinical outcomes for patients with END after stroke. The argatroban group demonstrated superior efficacy compared to the control group.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Резюме
This study aimed to evaluate the efficacy and safety of argatroban combined with dual antiplatelet therapy (DAPT) in managing early neurological deterioration (END) following stroke and to determine whether argatroban offers superior outcomes compared to DAPT alone.
Почему это важно для гирудотерапии
В данном исследовании оценивался аргатробан в комбинации с двойной антитромбоцитарной терапией (ДАТ) в сравнении с ДАТ-alone при раннем неврологическом ухудшении после инсульта; в группу аргатробана были включены 30 пациентов, в контрольную — 50, с оценкой тяжести инсульта по шкале NIHSS в разные временные точки и функциональных исходов по модифицированной шкале Рэнкина. В группе аргатробана отмечено статистически значимое более выраженное снижение баллов по шкале NIHSS на 7-й и 14-й дни, хотя доля благоприятных исходов (mRS 0–2) не достигла статистической значимости. В группе аргатробана зафиксирован один эпизод десневого кровотечения. Релевантность к сфере ASH в лучшем случае косвенная: аргатробан является антикоагулянтом, однако исследование не включает пиявок, секретом пиявок или гирудин, и в реферате не приводится механистических деталей, связывающих его с гирудотерапией.
Цитирование
Argatroban plus dual antiplatelet therapy: Preliminary evidence for managing early neurological deterioration after lacunar stroke
Zhang H et al. · Clinical neurology and neurosurgery, 2025
Связанный клинический контекст
Узнайте, как это исследование связано с клинической практикой
Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: 18 июня 2026 г.